Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

13:24
 
Share
 

Manage episode 497633417 series 1044916
Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’
  continue reading

371 episodes

Artwork
iconShare
 
Manage episode 497633417 series 1044916
Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’
  continue reading

371 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play